Pα+ Psychedelic Bulletin #169: Brin Backs Soneira, But Patent Questions Loom Large; J&J Seeks Spravato Monotherapy Approval; Canadian Study to Parse Out Role of Psychotherapy
- Sergey Brin Bets $15M on Ibogaine Startup Soneira, But Questions Loom Over Patents
- Head-to-Head Trial Hopes to Assess Role of Psychotherapy in Psilocybin Treatment
- J&J Seeks FDA Approval of Spravato as Monotherapy
- Other Stories
Sergey Brin Bets $15M on Ibogaine Startup Soneira, But Questions Loom Over Patents
Google co-founder and psychedelics dabbler Sergey Brin looks set to fill $15M of a $25M round by ibogaine biotech Soneira Bio, which hopes to develop the drug for traumatic brain injury (TBI). Murmurings of the startup and its potential suitors have been doing the rounds for more than a year, with excitement abounding among the likes of the Jurvetsons and Brin...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In